Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis.

Of note, the effect size was smaller or showed a marginal trend toward standard anticoagulation in patients with provoked VTE; a more robust follow-up and health service contact may explain the almost equivalent response to rivaroxaban.

also in 626 other papers

Similarly, the ACTS Benefits scores showed a numerical trend in favor of rivaroxaban.

also in 1,012 other papers

The differences in ACTS Benefits scores were numerically in favor of rivaroxaban versus standard anticoagulation treatment in XALIA, although this did not reach statistical significance.

also in 111,027 other papers